Drug Search Results
More Filters [+]

SGN-30

Alternative Names: sgn-30, sgn30, sgn 30
Latest Update: 2021-03-22
Latest Update Note: News Article

Product Description

SeaGen is developing SGN-30, an intravenously administered recombinant anti-CD30 monoclonal antibody for the potential treatment of Hodgkin's disease, certain non-Hodgkin's lymphomas, specific leukemia, and immunological diseases such as multiple sclerosis and systemic lupus erythematosus. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/16610770/)

Mechanisms of Action: CD30 Antagonist

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SGN-30

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hodgkin Lymphoma|Lymphoma, B-Cell|Sarcoma, Kaposi|T-Cell Cutaneous Lymphoma|Large-Cell Anaplastic Lymphoma|Lymphomatoid Papulosis|Primary Cutaneous Anaplastic Large Cell Lymphoma|Lymphoma, Non-Hodgkin

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCI-2009-00162

P2

Terminated

Large-Cell Anaplastic Lymphoma|Lymphoma, Non-Hodgkin

2010-05-01

NCI-2009-00407

P2

Terminated

Lymphoma, Non-Hodgkin|Large-Cell Anaplastic Lymphoma

2010-01-01

NCI-2012-02822

P2

Completed

Hodgkin Lymphoma

2008-09-01

SG030-0004

P2

Completed

Primary Cutaneous Anaplastic Large Cell Lymphoma|Large-Cell Anaplastic Lymphoma|Lymphoma, Non-Hodgkin|Lymphomatoid Papulosis

2007-02-01

Recent News Events